



Tyra Biosciences Announces Participation at Upcoming Investor Events

August 20, 2025

CARLSBAD, Calif., Aug. 20, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that members of company management will participate in the following investor events:

Virtual H.C. Wainwright "HCW@Home" series
Format: Fireside chat
Presentation Date/Time: Thursday, August 21, 2025, at 11 AM ET

H.C. Wainwright 27th Annual Global Investment Conference
Format: Fireside chat and one-on-one investor meetings
Presentation Date/Time: Wednesday, September 10, 2025, at 9 AM ET
Location: New York, NY

A live webcast of the events can be accessed by visiting the "For Investors" page on the Tyra Biosciences [website](#) and will be available for replay following the event.

About Tyra Biosciences

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. TYRA's in-house precision medicine platform, SNÁP, enables rapid and precise drug design through iterative molecular SNÁPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's expertise in FGFR biology has created a differentiated pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. TYRA's lead precision medicine stemming from SNÁP, dabogratinib, is a potential first-in-class selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for FGFR3 gatekeeper mutations. The current planned clinical development for dabogratinib includes SURF302 for intermediate risk non-muscle invasive bladder cancer, BEACH301 for pediatric achondroplasia, and potentially future metastatic urothelial cancer studies. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma. TYRA is based in Carlsbad, CA.

For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on [LinkedIn](#).

Contact:

Amy Conrad
aconrad@tyra.bio



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/tyra-biosciences-announces-participation-at-upcoming-investor-events-302534890.html>

SOURCE Tyra Biosciences